Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine

Overview

Journal Ann Surg

Specialty General Surgery

Date 1992 Oct 1

PMID 1417196

Citations 58

Authors

D L Morton

L J Foshag

D S Hoon

J A Nizze

E Famatiga

L A Wanek

C Chang

D G Davtyan

R K Gupta

R Elashoff

Affiliations

Soon will be listed here.

Abstract

A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to MCV (p = 0.0117). Of 40 patients with evaluable disease, nine (23%) had regressions (three complete). From our historical database of 126 stage IIIA and 1275 stage IV melanoma patients, there were no significant changes in the natural history of metastatic melanoma during the past 20 years. Univariate and multivariate analyses demonstrated prognostic significance for site of metastases (p = 0.0001) and immunotherapy with the new MCV (p = 0.0001). Overall our new MCV increased the median and 5-year survival of stage IIIA melanoma patients with regional soft tissue metastases twofold (p = 0.00024), and stage IV patients threefold (p = 0.0001) compared with previous immunotherapy and other treatments.

Citing Articles

Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.

Devaraja K, Singh M, Sharan K, Aggarwal S Biomedicines. 2025; 12(12.

PMID: 39767654 PMC: 11726767. DOI: 10.3390/biomedicines12122746.

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics.

Dwivedi R, Jain A, Gupta S, Chandra S Indian J Otolaryngol Head Neck Surg. 2024; 76(3):2257-2272.

PMID: 38883453 PMC: 11169205. DOI: 10.1007/s12070-024-04565-3.

Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.

Schunke J, Mailander V, Landfester K, Fichter M Int J Mol Sci. 2023; 24(15).

PMID: 37569548 PMC: 10419017. DOI: 10.3390/ijms241512174.

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.

Dillman R, Nistor G, Keirstead H Hum Vaccin Immunother. 2023; 19(1):2198467.

PMID: 37133853 PMC: 10294766. DOI: 10.1080/21645515.2023.2198467.

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.

Berois N, Pittini A, Osinaga E Cancers (Basel). 2022; 14(3).

PMID: 35158915 PMC: 8833780. DOI: 10.3390/cancers14030645.

References

Saxton R, Irie R, Ferrone S, Pellegrino M, Morton D . Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients. Int J Cancer. 1978; 21(3):299-306. DOI: 10.1002/ijc.2910210308. View

Morton D, Eilber F . Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms. Natl Cancer Inst Monogr. 1971; 34:103-8. View

Morton D, Eilber F, Holmes E, Ramming K . Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust N Z J Surg. 1978; 48(1):49-52. DOI: 10.1111/j.1445-2197.1978.tb05804.x. View

Goodnight Jr J, Moseley H, Eilber F, Sarna G, Morton D . Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep. 1979; 63(11-12):2005-7. View

Gupta R, Morton D . Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst. 1983; 70(6):993-1004. View

Tai T, Paulson J, Cahan L, Irie R . Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A. 1983; 80(17):5392-6. PMC: 384262. DOI: 10.1073/pnas.80.17.5392. View

Griswold D, Alessi S, Badger A, Poste G, Hanna N . Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol. 1984; 132(6):3054-7. View

Cheresh D, Varki A, Varki N, Stallcup W, Levine J, Reisfeld R . A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem. 1984; 259(12):7453-9. View

Ceuppens J, Goodwin J . Prostaglandins and the immune response to cancer (review). Anticancer Res. 1981; 1(2):71-8. View

10.

Fossati G, Taramelli D, Balsari A, Bogdanovich G, Andreola S, Parmiani G . Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer. 1984; 33(5):591-7. DOI: 10.1002/ijc.2910330508. View

11.

Cahan L, Irie R, Singh R, Cassidenti A, Paulson J . Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A. 1982; 79(24):7629-33. PMC: 347401. DOI: 10.1073/pnas.79.24.7629. View

12.

Gupta R, Morton D . Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay. J Natl Cancer Inst. 1984; 72(1):67-74. DOI: 10.1093/jnci/72.1.67. View

13.

Guerry 4th D, Alexander M, Herlyn M, Zehngebot L, Mitchell K, ZMIJEWSKI C . HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest. 1984; 73(1):267-71. PMC: 425010. DOI: 10.1172/JCI111201. View

14.

Balch C, Soong S, Murad T, Smith J, Maddox W, DURANT J . A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983; 1(2):126-34. DOI: 10.1200/JCO.1983.1.2.126. View

15.

Jones P, Sze L, Liu P, Morton D, Irie R . Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981; 66(2):249-54. View

16.

Tanigawa N, Kern D, Hikasa Y, Morton D . Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res. 1982; 42(6):2159-64. View

17.

Morton D, Eilber F, Malmgren R, Wood W . Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970; 68(1):158-63; discussion 163-4. View

18.

Storm F, Sparks F, Morton D . Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion. Surg Gynecol Obstet. 1979; 149(1):17-21. View

19.

Roth J, Morton D, Holmes E . Rejection of dinitrochlorobenzene-conjugated syngeneic tumor cells by dinitrochlorobenzene-sensitized guinea pigs. J Surg Res. 1978; 25(1):1-7. DOI: 10.1016/0022-4804(78)90148-8. View

20.

Hayashi Y, Hoon D, Park M, Terasaki P, Morton D . Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunol Immunother. 1992; 34(6):419-23. PMC: 11038150. DOI: 10.1007/BF01741754. View